logo

Contact information

Dr. med. Ron Jachimowicz
Dr. med. Ron Jachimowicz

Department I of Internal Medicine

University Hospital of Cologne

Kerpener Straße 62 

50937 Cologne

 

Max Planck Institute for Biology of Ageing

Joseph-Stelzmann-Strasse 9b

50931 Cologne

CV

Academic education

2003 - 2010 Medical School, University of Cologne

 

Scientific degrees

02/2011 MD thesis, Department I of Internal Medicine, University of Cologne, Advisor:  Prof. Dr. E. P. von Strandmann and Prof. Dr. A. Engert
06/2010 Graduation from Medical School, University of Cologne

 

Scientific career

2022 - present Steering Group Member "Leuchtturm Alternsmedizin" NRW
2021 - present Attending Physician, University Hospital Cologne
2020 - present Max Planck Research Group Leader, MPI-Age
2020 - present CECAD Associated Principal Investigator, Excellence Cluster CECAD, University of Cologne, Germany
2020 - present CMMC Associated Principal Investigator, Center for Molecular Medicine, University of Cologne, Germany
2020 - present Co-Speaker of the Else Kröner Research College: Clonal evolution in cancer
2020 - present Co-Head of Cologne Lymphoma Working Group, University Hospital Cologne
2017 - 2020 Resident Physician at the Department I of Internal Medicine, University Hospital Cologne
2017 - 2019 Postdoctoral Research Fellow, Department I of Internal Medicine, University of Cologne, Germany, Advisor: Prof. Dr. H.C. Reinhardt
2014 - 2017 Postdoctoral Research Fellow, The David and Inez Myers Laboratory of Cancer Genetics, Sackler School of Medicine, University of Tel Aviv, Israel, Advisor: Prof. Dr. Y. Shiloh
2013 - 2014 Postdoctoral Research Fellow, Department I of Internal Medicine, University of Cologne, Germany, Advisor: Prof. Dr. H.C. Reinhardt
2010 - 2014 Resident Physician at the Department I of Internal Medicine, University Hospital of Cologne

 

Honors/ Awards/ Memberships

2021 Best publication award of the Medical Faculty, University of Cologne
2020  Theodor-Frerichs-Award of the German Society of Internal Medicine
2017 - 2019 Else Kröner Forschungskolleg Postdoctoral Fellowship, “Clonal Evolution in Cancer”, University Hospital of Cologne
2014 - 2017 German Research Foundation (DFG) Postdoctoral Fellowship (JA 2439/1-1)

Publications

  • Mouse models of diffuse large B cell lymphoma

    Diffuse large B cell lymphoma (DLBCL) is a genetically highly heterogeneous disease. Yet, to date, the vast majority of patients receive standardized frontline chemo-immune-therapy consisting of an anthracycline backbone. Using these regimens, approximately 65% of patients can be cured, whereas the…

    Link to the publication

  • An inducible Cd79b mutation confers ibrutinib sensitivity in mouse models of Myd88-driven diffuse large B-cell lymphoma

    - In mouse models of Myd88-driven DLBCL, the presence of a Cd79b ITAM mutation results in increased BCR proximal signaling. - The increased BCR signaling activity in Cd79b-mutated models confers a selective ibrutinib sensitivity. Diffuse large B cell lymphoma (DLBCL) is the most common…

    Link to the publication

  • Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies

    Genomic profiling revealed the identity of at least 5 subtypes of diffuse large B-cell lymphoma (DLBCL), including the MCD/C5 cluster characterized by aberrations in MYD88, BCL2, PRDM1, and/or SPIB. We generated mouse models harboring B cell–specific Prdm1 or Spib aberrations on the background of…

    Link to the publication

  • Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP

    Link to the publication

  • UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors

    Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders. UBQLN4 deficiency leads to increased sensitivity to genotoxic stress and delayed DNA…

    Link to the publication

  • Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma

    Resistance to standard cisplatin-based chemotherapies leads to worse survival outcomes for patients with esophageal squamous cell carcinoma (ESCC). Therefore, there is an urgent need to understand the aberrant mechanisms driving resistance in ESCC tumors. We hypothesized that ubiquilin-4 (UBQLN4), a…

    Link to the publication

  • Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP

    A subset of patients with advanced-stage classical Hodgkin Lymphoma (cHL) relapse or progress following standard treatment. Given their dismal prognosis, identifying this group of patients upfront represents an important medical need. While prior research has identified characteristics of the tumor…

    Link to the publication
Back to all principal investigators